On August 6, 2026, digital pathology company Proscia announced that the U.S. Food and Drug Administration had granted a new 510(k) clearance for its Concentriq AP-Dx platform, a system pathologists use to review tissue slides on screen instead of under a microscope in order to render primary cancer diagnoses. The clearance is notable less for what it adds today than for the mechanism behind it: a Predetermined Change Control Plan, or PCCP, that lets Proscia roll out certain future upgrades to hospitals and labs without filing a fresh application with regulators each time.
What the Clearance Actually Covers
The immediate, tangible changes are compatibility with Leica’s Aperio GT 450 DX slide scanner and the addition of a cloud deployment option for laboratories that want to run the platform off-site rather than on local servers. Concentriq AP-Dx first won FDA clearance for primary diagnosis in February 2024, when it was validated for use with Hamamatsu’s NanoZoomer S360MD scanner. Since then, Proscia has been expanding the hardware ecosystem the software can plug into, and the Leica scanner support is the latest addition on that front.
Ian Cadieux, Proscia’s head of quality and regulatory affairs, said in the company’s announcement that laboratories select a digital pathology platform expecting it to remain central to their operations for years, which is the rationale the company gives for building in a change-control mechanism up front rather than treating every scanner addition as a one-off regulatory event.
Why a Change Control Plan Matters
Historically, any modification to an FDA-cleared AI or software-based diagnostic device, even something as narrow as adding support for a new scanner model, could trigger the need for a new 510(k) submission. That process can take months and adds friction for companies trying to keep pace with hospital IT environments. The PCCP framework, which the FDA has been developing specifically for adaptive, frequently updated medical software and AI tools, allows a company to pre-specify the types of changes it plans to make and the testing protocol it will follow, then make those changes going forward without waiting for individual sign-off on each one. Proscia’s clearance lets it validate and add support for additional FDA-cleared scanners, image formats, and displays under that pre-agreed plan.
The Scale of What’s at Stake
Proscia says its platform is used by laboratories that collectively manage around 12 million patient cases a year, and the company points to a projected 2.1 million new cancer diagnoses in the United States in 2026 as the backdrop against which pathology throughput matters. The company also says it works with 16 of the top 20 pharmaceutical companies, reflecting a second customer base beyond hospital labs: drug developers who use digital pathology to score biopsies in clinical trials. Proscia was ranked first in KLAS Research’s 2026 Digital Pathology report for supporting customers’ integration goals and for overall performance, a research firm ranking that is often used by health system IT buyers to compare vendors.
Digital Pathology’s Slow, Steady Rollout
Digital pathology, the practice of scanning glass slides into high-resolution digital images that pathologists read on a monitor, has been adopted more slowly in the U.S. than in parts of Europe and Asia, partly because of the regulatory bar for primary diagnosis use and partly because of the cost of scanners and storage. Proscia’s approach of pursuing narrow, sequential clearances covering specific scanner models is one of the more visible examples of how vendors are trying to clear that bar piece by piece rather than all at once. The company is also CE-marked under Europe’s In Vitro Diagnostic Regulation, giving it regulatory standing on both sides of the Atlantic.
Caveats and What Comes Next
A PCCP does not mean unlimited, unsupervised change. The FDA still requires the company to follow the validation protocol it committed to, and any change outside the pre-specified scope would still need its own submission. Critics of accelerated software-update pathways for medical devices have argued that even pre-approved change plans can make it harder for outside clinicians and researchers to know exactly which version of an algorithm produced a given result, since the software can evolve incrementally between formal review cycles. For now, Proscia’s near-term plan is to keep adding scanner and display compatibility under the new plan, which should make it easier for hospital and reference labs already invested in Leica or Hamamatsu hardware to adopt the platform without re-architecting their imaging pipeline, a step that digital pathology vendors broadly see as necessary to accelerate replacement of the microscope as the default diagnostic tool in anatomic pathology.
